Examine the Effectiveness of Cancer Screening Among Patients with Alzheimer’s Disease and Related Dementias Using Real-World Data

摘要 通过筛查及早发现癌症大大增加了成功治疗的机会，因此 为降低癌症死亡率和减轻人群癌症负担提供了最好的机会。 国家专业协会，如美国预防服务工作组(USPSTF)和 美国癌症协会制定了各种癌症的筛查指南，其基础是 对科学证据的广泛审查。这些指南确定了符合癌症筛查条件的人群和 就筛查测试的类型和频率提供建议。然而，即使有证据- 根据筛查指南，做出接受癌症筛查的决定并不总是一帆风顺的，尤其是 适用于阿尔茨海默病和相关痴呆(ADRD)患者。ADRD患者患有贫困 功能状态、并存疾病和预期寿命缩短。对ADRD患者进行癌症筛查可能 导致对癌症的过度诊断和治疗，否则不会在 病人的一生。另一方面，癌症筛查测试有效性的关键证据是 降低晚期癌症发病率和死亡率，这通常是在随机临床试验中获得的 (RCT)。然而，癌症筛查的随机对照试验需要长期的随访。在ADRD进行这些RCT 患者是一群身体和认知能力受损的人群，他们可能在后勤、经济和 在道德上具有挑战性。到目前为止，尚不清楚癌症筛查是否真的能降低美国的死亡率。 这群人。在我们的父级奖项R01 CA246418中，我们开发了研究级可计算程序 表型(CP)，用于识别符合或不符合肺癌筛查(LCS)条件的个人 One佛罗里达网络中的结构化和非结构化EHR数据。我们很快就会开始研究 适当和不适当的LC的使用模式和预测因素，并估计收益和成本- LCS的有效性。One佛罗里达是由PCORI资助的9个研究网络之一，为国家 PCORnet。它包含大约1,500万名患者的电子病历，与来自各种其他来源的数据相链接，包括医疗补助 以及医疗保险索赔、癌症登记和生命统计数据。在这份行政副刊中，我们建议 确定One佛罗里达州ADRD患者的回溯性队列：(1)检查使用模式和 ADRD患者中肺癌、乳腺癌和结直肠癌筛查的预测因素和(2)测试是否癌症 筛查可降低ADRD患者的晚期癌症发病率和死亡率。这项研究将是第一次 检查癌症筛查在降低晚期癌症诊断率和死亡率方面的有效性。 ADRD患者。鉴于随机对照试验的不可行性，我们的研究将提供关键的证据，可以帮助临床医生， 照顾者和家庭从数量上了解癌症筛查的有效性，并决定 癌症筛查对ADRD患者是否有用。

ABSTRACT Detecting cancer early through screening substantially increases the chance of successful treatment, and thus provides the best opportunity for reducing cancer mortality and alleviating cancer burden in the population. National professional associations such as the US Preventive Services Task Force (USPSTF) and the American Cancer Society have developed screening guidelines for various types of cancers based on extensive reviews of scientific evidence. These guidelines identify cancer screening-eligible populations and provide recommendations on the type and frequency of screening tests. However, even with the evidence- based screening guidelines, a decision to undergo cancer screening is not always straightforward, especially for patients with Alzheimer's disease and related dementias (ADRD). ADRD patients suffer from poor functional status, comorbid illnesses, and shortened life expectancy. Screening ADRD patients for cancer may lead to over-diagnosis and treatment of cancers that otherwise would not have caused symptoms during a patient’s lifetime. On the other hand, the key evidence on the effectiveness of a cancer screening test is the reduction in late-stage cancer incidence and mortality, which is often obtained in randomized clinical trials (RCTs). However, RCTs of cancer screening require a long follow-up. Conducting these RCTs in ADRD patients, a population of compromised physical and cognitive abilities, can be logistically, financially, and ethically challenging. To date, it remains unclear whether cancer screening can actually reduce mortality in this population. In our parent award R01 CA246418, we have developed research-grade computable phenotypes (CP) for identifying individuals who are eligible or ineligible for lung cancer screening (LCS) using both structured and unstructured EHR data in the OneFlorida network. We will soon begin to examine the utilization patterns and predictors of appropriate and inappropriate LCS, and estimate the benefits and cost- effectiveness of LCS. OneFlorida is one of the 9 PCORI-funded research networks contributing to the national PCORnet. It contains ~15 million patient EHRs linked with data from various other sources, including Medicaid and Medicare claims, cancer registries, and vital statistics. In this administrative supplement, we propose to identify a retrospective cohort of ADRD patients in OneFlorida to: (1) examine the utilization patterns and predictors of lung, breast, and colorectal cancer screening among ADRD patients and (2) test whether cancer screening reduces late-stage cancer incidence and mortality among ADRD patients. This study will be the first to examine the effectiveness of cancer screening in reducing late-stage cancer diagnosis and mortality in ADRD patients. Given the infeasibility of RCTs, our study will provide critical evidence that can help clinicians, caregivers, and families understand the effectiveness of cancer screening in quantitative terms and decide whether cancer screening is useful in ADRD patients.